Centessa IPO Presentation Deck

SerpinPC: Status and Competition STATUS & UPCOMING MILESTONES Phase 2a multiple repeat dose study ongoing Early-to-mid 2021 Mid-to-late 2021 Mid-to-late 2022 • 6mo study of monthly subq dosing of SerpinPC at 3 dose levels in severe HA & HB +/-inhibitors patients • 23 subjects enrolled • Primary Objective: Safety and tolerability of SerpinPC • Secondary Objective: Assess pharmacokinetics of SerpinPC • Exploratory Objective: Explore effect of SerpinPC on annualized bleeding rate (ABR) and factor usage Start of 48-week open label extension study Data from 24-week Phase 2a multiple repeat dose study Data from 12-month open label extension study COMPETITIVE LANDSCAPE Emicizumab, recombinant, bispecific mAb treatment ~HA: Marketed (Roche) Concizumab, anti-TFPI mAb ~HB: Phase 3 (Novo Nordisk) Fitusiran, siRNA therapy "HB: Phase 3 (Sanofi) Valoctocogene roxaparvovec, AAV-FVIII gene therapy ~HA: Phase 3 (BioMarin) Fidanacogene elaparvovec, AAV-FIX gene therapy ~HB: Phase 3 (Pfizer / Spark) Apcintex CENTESSA 21

View entire presentation